N@N

Targacept to Host NNR Research and Development Day December 2nd

^{Published on 2010-11-22 07:35:29 - Market Wire}
 

WINSTON-SALEM, N.C.--([ BUSINESS WIRE ])--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), will host a NNR Research and Development Day on Thursday, December 2, 2010 at The Intercontinental New York Barclay Hotel in New York City beginning at 8:00 a.m. Eastern Time. The program will focus on developments and potential therapeutic applications in the NNR field and will include a panel discussion on Major Depressive Disorder (MDD) and Targacepta™s product candidate TC-5214 in development as an adjunct to first-line antidepressant therapy for MDD.

Scheduled speakers include:

• Ronald J. Lukas, Ph.D. a" Vice President of Research, Senior Staff Scientist and Director, Laboratory of Neurochemistry and Clinical Assay Development Laboratory, St. Josepha™s Hospital and Medical Center and Barrow Neurological Institute
• Kevin Tracey, M.D. a" Chief Executive Officer, The Feinstein Institute for Medical Research, and Professor and President, Elmezzi Graduate School of Molecular Medicine
• Maryka Quik, Ph.D. a" Program Director, Neurodegenerative Diseases Center for Health Sciences, SRI International
• Madhukar Trivedi, M.D. a" Professor of Psychiatry and Betty Jo Hay Distinguished Chair in Mental Health at the University of Texas Southwestern Medical School
• Marina Picciotto, Ph.D. a" Associate Professor of Psychiatry, Yale University
• John Ramsey, M.Phil. a" Vice President, Development, Seroquel & TC-5214, AstraZeneca
• Targacept management and scientists, including: J. Donald deBethizy, Ph.D. a" President and Chief Executive Officer; William S. Caldwell, Ph.D. a" Senior Vice President, Drug Discovery and Development; Geoffrey C. Dunbar, M.D. a" Senior Vice President, Clinical Development and Regulatory Affairs and Chief Medical Officer; David Hosford, M.D., Ph.D. a" Vice President, Clinical Development; and Daniel Yohannes, Ph.D. a" Senior Director of Drug Discovery.

For additional information, please contact Jo Peay at (336) 480-2102 or [ jo.peay@targacept.com ].

A live webcast of the event will be accessible from the Investor Relations page of Targacepta™s website, [ www.targacept.com ]. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Calendar section of the Investor Relations page of Targacept's website for at least two weeks following the call.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics(TM) for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Targacept's lead program, TC-5214, is in Phase 3 development as an adjunct treatment for major depressive disorder. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentad(TM) to generate novel small molecule product candidates to fuel its pipeline and attract significant collaborations with global pharmaceutical companies. For more information, please visit [ www.targacept.com ].

TARGACEPT

Building Health, Restoring Independencea"